Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient. Issue 5 (June 2016)

• Record Type: Journal Article
• Authors: Bonetta, Alberto; Bandera, Laura; Roviello, Giandomenico; Cafaro, Ines; Bottini, Alberto; Generali, Daniele
• Is Part Of: Anti-cancer drugs. Volume 27:Issue 5(2016)
• Publication Date: 2016-06
• Subjects: cetuximab -- laryngeal cancer -- neoadjuvant treatment -- radiotherapy -- recipient; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000352
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : The oncological treatment for advanced stage head and neck cancer is based on a combination of cisplatin and cetuximab, and radiotherapy. However, very few data are available on this multimodal approach for this type of cancer in pancreas and renal recipients. We report the case of a pancreas and renal recipient being treated with combined chemoradiotherapy for a locally advanced squamous cancer of the larynx. The patient was under treatment with ciclosporin-based immunosuppressive therapy at the time of cancer diagnosis, which was then replaced by everolimus. After 4 years of follow-up, the patients is still free from disease, with a local complete response, only mild residual dysphonia, and with edema of the chin. Cetuximab plus radiation could be an adequate option for cancer treatment in solid organ transplant recipients affected by locally advanced head and neck cancer; the concomitant use of mammalian target of rapamycin pathway inhibitors may have a synergistic effect in enhancing tumor control in these patients; however, further dedicated studies are warranted.